A Phase 1 interventional study of Inactivated Enterovirus Type 71 Vaccine and Placebo in Infection; Viral, Enterovirus, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-15.
Sponsored by Sinovac Biotech Co., Ltd · Phase 1, Interventional, and Prevention
A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type 71 Vaccines in healthy adults
A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they will be randomized to receive two different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine in adults
47 studies on the registry are indexed under Enterovirus Infections; 5 are open to participants now.
This study's enrollment of 36 is below the median of 150 across 31 interventional studies indexed under Enterovirus Infections.
Browse Enterovirus Infections studies →Sinovac Biotech Co., Ltd is the lead sponsor of 89 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
12 adults received 3 doses of 200U EV71 vaccine 14 days apart
Biological: Inactivated Enterovirus Type 71 Vaccine
12 adults received 3 doses of 400U EV71 vaccine 14 days apart
Biological: Inactivated Enterovirus Type 71 Vaccine
6 adults received 3 doses of placebo 14 days apart
Other: Placebo
6 adults received 3 doses of placebo 14 days apart
Other: Placebo
A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Also known as: EV71 Vaccine
Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Also known as: EV71 Vaccine
To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses
Time frame: 3 months
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sinovac Biotech Co., Ltd